Fig 2: The soluble release profile by activated T cells is altered by valproic acid, ATRA and cytarabine – a two-ways hierarchical cluster analysis. PBMCs derived from 7 healthy individuals were cultured with the T cell activating signal anti-CD3 plus anti-CD28 for 4 days before supernatants were harvested and cytokine levels determined. The cells were then cultured in drugfree control cultures and together with ATRA 1 μM, valproic acid 500 and 100 μM, and cytarabine 0.01, 0.35, 1 and 44 μM, and each drug was also tested in dual or triple combinations as indicated at the top of the figure. The overall results are presented in detail in Additional file 1: Table S1-S4. The results from a two-ways hierarchical cluster analysis including FasL, TRAIL, HSP70 and HSP90 together with 20 cytokines are presented in the figure. We investigated the levels of (i) the immunoregulatory cytokines IFNγ and TNFα; (ii) the growth factors G-CSF, GM,-CSF, VEGF and bFGF; (iii) the chemokines CCL2-5 and CXCL5; and (iv) the interleukins IL1α, IL1β, IL1RA, IL2, IL4-6, IL8, IL10 and IL17. The cytokines formed 4 main clusters as indicated on the left margin of the figure. The analysis included the 19 single drug/drug combinations used throughout the study and the various drugs/drug combinations formed three main clusters.

Fig 3: ROC curves of plasma HSP70 to predict AMI, STEMI, and total occlusion in target lesions. (A) Comparison of plasma HSP70 in patients with AMI and control patients with no AMI; (B) ROC curves of HSP70 to predict AMI, with an AUC of 0.7660 (95% CI 0.6946–0.8374) and best cutoff value of 0.713 ng/ml; (C) comparison of plasma HSP70 in patients with STEMI and control patients with no STEMI; (D) ROC curves of HSP70 to predict STEMI, with an AUC of 0.7152 (95% CI 0.6289–0.8015) and best cutoff value of 0.452 ng/ml; (E) comparison of plasma HSP70 in patients with total occlusion and control patients with no total occlusion; (F) ROC curves of HSP70 to predict total occlusion, with an AUC of 0.5984 (95% CI 0.5048–0.6920) and best cutoff value of 1.017 ng/ml. AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; ROC, receiver operating characteristic; AUC, area under the curve.

Fig 4: Comparison of HSP70 plasma levels (ng/ml) in SHAM and DJOS-operated groups subjected to the different dietary patterns pre- and post-surgery. Abbreviations: CD, control diet; HFS, high-fat, high-sugar diet. Vertical lines depict 95% confidence interval

Fig 5: Detailed comparison of plasma HSP70. (A) Comparison between overall patients with MI and CCS. (B) Matched-pairs comparison between day 1 and day 7 post-MI. (C) Matched-pairs comparison between day 1 and day 7 in STEMI and NSTEMI. (D) Comparison among patients with day 1 and day 7 post-MI, CCS with no CTO, and CCS with CTO lesions. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant; MI, myocardial infarction; MI1d, 1 day post-MI; MI7d, 7 days post-MI; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; CCS, chronic coronary syndrome; CTO, chronic total occlusion; NCTO, no chronic total occlusion.